Chicago: A team of researchers from the University of Chicago has made a significant advancement in cancer diagnostics by developing a highly accurate liquid biopsy test. This innovative test can detect colorectal cancer in its early stages with an impressive 95% accuracy rate.

According to Oman News Agency, traditional biopsy methods require invasive tissue removal, whereas liquid biopsies offer a less intrusive approach by analyzing blood samples for cancer markers. Despite their benefits, liquid biopsies have often struggled with early detection due to the low levels of cancer-specific DNA in the blood during the initial stages of the disease. However, the new test, spearheaded by Dr. Chuan He and his team, leverages RNA (ribonucleic acid) rather than DNA to pinpoint genetic alterations associated with cancer.

The trial results are promising, demonstrating that the test can accurately identify colorectal cancer from patient blood samples, even in the early stages. This breakthrough could potentially lead to earlier interventions and improved survival rates for individuals diagnosed with this type of cancer, marking a significant step forward in cancer research and treatment.